We give new life and purpose to an older drug, anagrelide, with targeted sarcoma therapy.

Sartar Therapeutics is developing a new precision medicine product, SAR001, to treat sarcomas. SAR001 specifically targets phosphodiesterase 3 protein-expressing tumors. SAR001 is based on drug reformulation and repositioning of anagrelide, an approved drug used to treat thrombocythemia, a blood disease characterized by platelet overproduction. SAR001 is a slow-release drug product that shows superior pharmacokinetic properties over older anagrelide products, making it more efficacious, better tolerated, and more convenient for use in therapy.